Modulation of MicroRNAs by Chemical Carcinogens and Anticancer Drugs in Human Cancer: Potential Inkling to Therapeutic Advantage.

Molecular and cellular pharmacology Pub Date : 2011-01-01
Subrata Haldar, Aruna Basu
{"title":"Modulation of MicroRNAs by Chemical Carcinogens and Anticancer Drugs in Human Cancer: Potential Inkling to Therapeutic Advantage.","authors":"Subrata Haldar, Aruna Basu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The disorder of microRNAs (miRNAs) often referred as 'micromanagers of gene expression' has been implicated with a vast array of neoplasmthe discovery establishes an important connection with the etiology, diagnosis and potential therapy of human cancer. Indeed, the wide range of profiling studies enabled to create miRNA signatures of solid tumors as well as cancers of blood origin. MiRNAs have been observed to play a significant role in the regulation of gene expression-a critical aspect of many biological processes, including cell development, differentiation, apoptosis and proliferation. The differential expression levels of miRNAs in tumors and their normal counterpart have enabled scientists to designate their roles as oncomir or tumor suppressor. Interestingly, the diminishment of oncogenic or enhanced levels of tumor suppressor miRNAs (antagomirs) have been reported to modulate the sensitivity of cancer cells to anticancer agents. To the other end, carcinogenic chemicals either possess the ability of silencing beneficial tumor suppressive miRNAs or maintain the augmented levels of their oncogenic counterpart. In this article we provide a comprehensive overview on the modulation of these \"micromanaging oligos\" by cancer causing as well as cancer preventing agents.</p>","PeriodicalId":18748,"journal":{"name":"Molecular and cellular pharmacology","volume":"3 3","pages":"135-141"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266367/pdf/nihms348617.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and cellular pharmacology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The disorder of microRNAs (miRNAs) often referred as 'micromanagers of gene expression' has been implicated with a vast array of neoplasmthe discovery establishes an important connection with the etiology, diagnosis and potential therapy of human cancer. Indeed, the wide range of profiling studies enabled to create miRNA signatures of solid tumors as well as cancers of blood origin. MiRNAs have been observed to play a significant role in the regulation of gene expression-a critical aspect of many biological processes, including cell development, differentiation, apoptosis and proliferation. The differential expression levels of miRNAs in tumors and their normal counterpart have enabled scientists to designate their roles as oncomir or tumor suppressor. Interestingly, the diminishment of oncogenic or enhanced levels of tumor suppressor miRNAs (antagomirs) have been reported to modulate the sensitivity of cancer cells to anticancer agents. To the other end, carcinogenic chemicals either possess the ability of silencing beneficial tumor suppressive miRNAs or maintain the augmented levels of their oncogenic counterpart. In this article we provide a comprehensive overview on the modulation of these "micromanaging oligos" by cancer causing as well as cancer preventing agents.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人类癌症中化学致癌物和抗癌药物对 MicroRNAs 的调节:治疗优势的潜在曙光。
被称为 "基因表达微观管理者 "的微小核糖核酸(miRNA)的紊乱与多种肿瘤有关,这一发现与人类癌症的病因、诊断和潜在治疗建立了重要联系。事实上,通过广泛的分析研究,我们已经建立了实体瘤和血源性癌症的 miRNA 特征。据观察,miRNA 在基因表达调控中发挥着重要作用,而基因表达调控是许多生物过程(包括细胞发育、分化、凋亡和增殖)的关键环节。由于 miRNA 在肿瘤和正常细胞中的表达水平不同,科学家们将它们的作用划分为肿瘤抑制因子或肿瘤诱导因子。有趣的是,据报道,致癌 miRNA 的减少或抑瘤 miRNA(抗组蛋白)水平的提高可调节癌细胞对抗癌药物的敏感性。另一方面,致癌化学物质要么具有抑制有益肿瘤抑制性 miRNAs 的能力,要么能维持其致癌对应物的增高水平。在本文中,我们将全面概述致癌和防癌药物对这些 "微管理寡核苷酸 "的调节作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
0
期刊最新文献
Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers. Protein Kinase D: A Potential Therapeutic Target in Prostate Cancer. RNA-binding Protein, GADD45-alpha, p27Kip1, p53 and Genotoxic Stress Response in Relation to Chemoresistance in Cancer. mTOR Inhibitors at a Glance. Curcumin-encapsulating Nanogels as an Effective Anticancer Formulation for Intracellular Uptake.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1